AXDX vs. BLI, AKYA, BNGO, PRE, RPID, OMIC, TLIS, ASTC, HLTH, and PRPO
Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Berkeley Lights (BLI), Akoya Biosciences (AKYA), Bionano Genomics (BNGO), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Singular Genomics Systems (OMIC), Talis Biomedical (TLIS), Astrotech (ASTC), Cue Health (HLTH), and Precipio (PRPO). These companies are all part of the "analytical instruments" industry.
Accelerate Diagnostics (NASDAQ:AXDX) and Berkeley Lights (NASDAQ:BLI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
17.1% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 68.4% of Berkeley Lights shares are owned by institutional investors. 43.6% of Accelerate Diagnostics shares are owned by company insiders. Comparatively, 17.6% of Berkeley Lights shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Accelerate Diagnostics presently has a consensus target price of $1.00, indicating a potential downside of 15.97%.
Accelerate Diagnostics received 346 more outperform votes than Berkeley Lights when rated by MarketBeat users. Likewise, 62.99% of users gave Accelerate Diagnostics an outperform vote while only 26.67% of users gave Berkeley Lights an outperform vote.
Accelerate Diagnostics has higher earnings, but lower revenue than Berkeley Lights. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Berkeley Lights, indicating that it is currently the more affordable of the two stocks.
Berkeley Lights has a net margin of -124.74% compared to Accelerate Diagnostics' net margin of -452.28%. Accelerate Diagnostics' return on equity of 0.00% beat Berkeley Lights' return on equity.
In the previous week, Accelerate Diagnostics had 5 more articles in the media than Berkeley Lights. MarketBeat recorded 5 mentions for Accelerate Diagnostics and 0 mentions for Berkeley Lights. Accelerate Diagnostics' average media sentiment score of 0.43 beat Berkeley Lights' score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the media.
Accelerate Diagnostics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Berkeley Lights has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
Summary
Accelerate Diagnostics beats Berkeley Lights on 9 of the 15 factors compared between the two stocks.
Get Accelerate Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accelerate Diagnostics Competitors List
Related Companies and Tools
